Compare Divis Laboratories with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AJANTA PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AJANTA PHARMA DIVIS LABORATORIES/
AJANTA PHARMA
 
P/E (TTM) x 32.5 23.5 138.3% View Chart
P/BV x 7.3 4.1 176.9% View Chart
Dividend Yield % 0.6 0.9 72.0%  

Financials

 DIVIS LABORATORIES   AJANTA PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
AJANTA PHARMA
Mar-19
DIVIS LABORATORIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1421,422 80.3%   
Low Rs533898 59.4%   
Sales per share (Unadj.) Rs146.6233.5 62.8%  
Earnings per share (Unadj.) Rs33.044.0 75.1%  
Cash flow per share (Unadj.) Rs38.452.2 73.6%  
Dividends per share (Unadj.) Rs10.009.00 111.1%  
Dividend yield (eoy) %1.20.8 153.9%  
Book value per share (Unadj.) Rs222.8255.1 87.4%  
Shares outstanding (eoy) m265.4788.02 301.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x5.75.0 115.0%   
Avg P/E ratio x25.326.4 96.1%  
P/CF ratio (eoy) x21.822.2 98.1%  
Price / Book Value ratio x3.84.5 82.7%  
Dividend payout %30.320.5 147.9%   
Avg Mkt Cap Rs m222,318102,081 217.8%   
No. of employees `00010.86.8 158.3%   
Total wages/salary Rs m4,5614,307 105.9%   
Avg. sales/employee Rs Th3,616.03,022.6 119.6%   
Avg. wages/employee Rs Th423.8633.4 66.9%   
Avg. net profit/employee Rs Th814.9569.1 143.2%   
INCOME DATA
Net Sales Rs m38,91520,554 189.3%  
Other income Rs m1,134211 538.1%   
Total revenues Rs m40,04920,765 192.9%   
Gross profit Rs m12,6175,664 222.7%  
Depreciation Rs m1,425721 197.7%   
Interest Rs m1312 114.7%   
Profit before tax Rs m12,3135,143 239.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,5431,273 278.3%   
Profit after tax Rs m8,7703,870 226.6%  
Gross profit margin %32.427.6 117.6%  
Effective tax rate %28.824.8 116.2%   
Net profit margin %22.518.8 119.7%  
BALANCE SHEET DATA
Current assets Rs m45,35111,812 383.9%   
Current liabilities Rs m6,5073,776 172.3%   
Net working cap to sales %99.839.1 255.3%  
Current ratio x7.03.1 222.8%  
Inventory Days Days12777 163.7%  
Debtors Days Days9582 116.6%  
Net fixed assets Rs m21,16014,398 147.0%   
Share capital Rs m531175 302.7%   
"Free" reserves Rs m58,62522,277 263.2%   
Net worth Rs m59,15622,452 263.5%   
Long term debt Rs m07 0.0%   
Total assets Rs m67,83226,962 251.6%  
Interest coverage x926.8444.3 208.6%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 75.3%   
Return on assets %12.914.4 90.0%  
Return on equity %14.817.2 86.0%  
Return on capital %20.823.0 90.8%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35910,682 302.9%   
Fx outflow Rs m9,0422,102 430.2%   
Net fx Rs m23,3178,580 271.8%   
CASH FLOW
From Operations Rs m7,7593,748 207.0%  
From Investments Rs m-4,783-2,228 214.7%  
From Financial Activity Rs m-3,142-1,475 213.0%  
Net Cashflow Rs m-16645 -367.3%  

Share Holding

Indian Promoters % 52.0 73.8 70.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 1.6 761.3%  
FIIs % 19.0 7.6 250.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 17.0 101.2%  
Shareholders   31,796 20,968 151.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ASTRAZENECA PHARMA  ALEMBIC PHARMA  WOCKHARDT  NOVARTIS  DR. DATSONS LABS  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

WPI Inflation Data, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Monday, Indian share markets witnessed negative trading activity throughout the day and ended lower.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY20); Net Profit Up 0.4% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.4% YoY). Sales on the other hand came in at Rs 11 bn (up 14.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 8.4% (Quarterly Result Update)

Aug 2, 2019 | Updated on Aug 2, 2019

For the quarter ended June 2019, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 8.4% YoY). Sales on the other hand came in at Rs 6 bn (up 19.8% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of AJANTA PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AJANTA PHARMA. Also includes updates on the valuation of AJANTA PHARMA.

DIVIS LABORATORIES Announces Quarterly Results (4QFY19); Net Profit Up 10.6% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 10.6% YoY). Sales on the other hand came in at Rs 13 bn (up 15.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 5.9% (Quarterly Result Update)

May 3, 2019 | Updated on May 3, 2019

For the quarter ended March 2019, AJANTA PHARMA has posted a net profit of Rs 889 m (down 5.9% YoY). Sales on the other hand came in at Rs 5 bn (down 2.9% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Sep 17, 2019 09:39 AM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - PLETHICO PHARMA COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS